Enteral Feeding Formulas Market Size, Share & Trends Analysis Report By Product, By Flow Type, By Stage (Adult, Pediatric), By Indication, By End-user, By Region, And Segment Forecasts, 2021 - 2028

Report Overview

The global enteral feeding formulas market size was valued at USD 5.9 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 5.9% from 2021 to 2028. The growing prevalence of chronic diseases, such as cancer, stroke, multiple sclerosis, dementia, chronic liver disease, Chronic Obstructive Pulmonary Disease (COPD), and diabetes, is projected to drive the demand for products that support patients with oral intake issues. In addition, the rise in preterm births is one of the significant factors boosting the demand for enteral feeding formulas to meet the nutritional requirements of newborns.

Furthermore, the increasing launch of new products is a key factor affirmatively impacting the growth of tube feeds. For instance, Victus, Inc. announced the launch of ABINTRA Care, in 2020, which is specialized nutrition that can support the immune system. This is expected to help the company increase its product portfolio in the specialized nutrition segment. In addition, the rising number of home health agencies and nursing care is also driving the demand, as these facilities support patients in post-surgery recovery. Such agencies serve a large number of elderly people facing difficulty in swallowing, which is expected to boost the adoption rate of enteral feeding formulas, thereby fueling market growth.

In addition, technological advancements and innovations in products are some of the other factors boosting the growth of the market for an enteral feeding formula. The broad product portfolio and robust product developments offered by key players in the market are positively impacting the market growth. Ready-to-drink (RTD), ready-to-use nutritional supplements, and tube feed along with tube feed for certain specific indications are some of the product categories gaining traction in recent years. For instance, PulmoCare, offered by Abbott, is a therapeutic nutrition feed for people suffering from COPD.

Furthermore, the risk of frailty and malnutrition amongst the geriatric population with comorbidities, such as diabetes, stroke, dementia, and depression, is much higher mainly due to various age-related changes in muscle mass and body composition. This often results in reduced ability to carry out or perform Activities of Daily Living (ADLs), thereby increasing the risk of injuries or falls. Therefore, it is important to analyze the pathophysiology behind the condition, mainly, nutritional deficiency. The increasing prevalence of conditions, such as malnutrition and anemia is likely to boost the adoption of enteral feeding formulas in the coming years. For instance, According to The Lancet published in 2020, around 33% of the world population was affected with anemia.

In addition, the rising number of COVID-19 cases in various geographies coupled with a large geriatric population, susceptible to various health conditions, are among the factors contributing to the growth of the market. In addition, weakened immunity and health due to comorbidities increase the severity of COVID-19 in the geriatric population. This is expected to increase the adoption of enteral feeding formulas and processes. For instance, according to an article published in Europe PMC in 2020, enteral nutrition is generally preferred over parenteral nutrition for COVID-19 patients admitted to the ICUs. In addition, it should be provided within 48 hours of admission. Hence, such instances signify increasing adoption of enteral feeding formulas during the pandemic.

Moreover, lack of understanding and awareness with respect to clinical nutrition in the medical and healthcare community is limiting its adoption and growth. Furthermore, clinical nutrition needs a prescription and higher supervision by medical professionals which further limits the growth of the market. In addition, although these products are gaining acceptance, they are not completely understood by physicians, patients, and pharmacists. This is one of the major factors that prevent doctors from prescribing, recommending, or adopting clinical nutrition, thereby restraining market growth. 

Product Insights

Based on product type, standard formulas dominated the market and accounted for the largest revenue share of 54.0% in 2020. This high share is attributable to the availability of a wide variety of standard formulas coupled with increased demand for low-cost nutrient formulations. In addition, the demand with respect to standard tube feeds is significant among the volume-sensitive patients or the patients on fluid restrictions. Such conditions include renal failure, congestive heart failure, and Syndrome of Inappropriate Antidiuretic Hormone (SIADH).

In addition, the disease specific formulas segment is anticipated to grow at the fastest rate during the forecast period. The high prevalence of chronic diseases, such as cancer, diabetes, and liver failure, is propelling the demand for disease-specific formulas. In addition, recent product developments to cater to specific nutritional requirements of various diseases are expected to boost the demand in the coming years. NOVASOURCE RENAL by Nestlé Health Science and SUPLENA by Abbott are examples of standard tube feeds used in patients with Chronic Kidney Disease (CKD).

Flow Type Insights

In 2020, based on flow type, intermittent feeding flow type accounted for the highest revenue share of 94.5% in the market. This is because intermittent feeding has shown better tolerance in patients as compared to bolus feeding. Moreover, this type of feeding does not require feeding pumps, which is helpful in allowing greater mobility in between the feedings. This is expected to increase its adoption among the hospital as well as homecare settings, thereby affirmatively impacting the segment growth.

In addition, the continuous feeding flow type segment is expected to witness the highest CAGR over the forecast period. The lower feeding rate of continuous feeding flow as compared to intermittent feeding is one of the major factors responsible for the lucrative growth of the segment. Continuous tube feeding is recommended for critically ill patients suffering from conditions such as respiratory failure, severe burns, and cancer. The increasing prevalence of such conditions is anticipated to propel the growth of the continuous feeding flow type segment during the forecast period.

Stage Insights

In 2020, based on stage, the adults' segment accounted for the highest revenue share of 88.4% in the market. The segment is projected to witness the fastest CAGR over the forecast period. The rising adoption of tube feeds in adults is one of the crucial factors driving the growth. In addition, the availability of large number of tube feeds or products for adults on a commercial level also contributes to the large share held by the segment. Glucerna, Osmolite, TwoCal, Vital, Promote, and Jevity are some of the popular brands by Abbott Nutrition for adults. 

Furthermore, increasing demand for tube feeds among pregnant women is also one of the major factors driving the market for the adult segment. In addition, pregnant women frequently suffer from hyperemesis gravidarum, which is categorized by severe vomiting and nausea, which may lead to a deficiency of vital nutrients and dehydration. According to a research study conducted by Mount Mary University, enteral nutrition showed successful pregnancy outcomes in women suffering from hyperemesis gravidarum. Moreover, increasing demand for tube feeds among patients suffering from neurovascular disorders is positively impacting the market growth.

Indication Insights

Based on indications, others' segment dominated the market and accounted for the largest revenue share of 42.7% in 2020. The segment is followed by cancer care, which accounted for a significant share of 24.0% in terms of revenue in 2020. The increasing prevalence of cancer and other health conditions associated with cancer is likely to promote the growth of the segment. For instance, according to GLOBOCON 2020, there were around 19.3 million new cases of cancer worldwide in 2020. Europe accounted for about 23.4% of total cancer cases and Asia had the highest population suffering from cancer, which was about 60%. 

Cancer weakens immunity and leads to loss of energy, which results in malnutrition in 40% to 80% of the cases. This affects the response to the treatment as well as increases treatment-related toxicity. Hence, to maintain nutrition and positive nitrogen balance, tube feeding is used, thereby fueling the market growth. Major players, such as Abbott Laboratories, provide liquid formulations that can be tube fed to cancer patients, to help maintain their nutrient balance. For instance, Jevity 1.5 Cal is prescription-based nutrition that is useful for cancer patients.

End-user Insights

In 2020, based on end user, the homecare segment accounted for the highest revenue share of 56.1% in the market. The segment is projected to witness the fastest CAGR over the forecast period. The increasing number of patients that receive home enteral feeding due to growing awareness about complete and balanced nutrition is one of the key factors contributing to the growth of this segment. For instance, according to a recent survey conducted in the U.K., there were 187 patients on home enteral tube feeding out of the total 257 patients. This suggested that approximately 72% of patients were on home enteral tube feeding.

Furthermore, rising awareness regarding enteral feeding formulas among home-based healthcare patients and increasing government intervention for educating the patient population with regards to the utilization of enteral feeding systems or pumps are some of the other factors boosting segment growth.

Regional Insights

North America dominated the enteral feeding formulas market and accounted for the largest revenue share of 29.7% in 2020 owing to the growing burden of chronic diseases such as diabetes, cancer, and other neurological conditions. Furthermore, increasing preference for home-based enteral therapy has decreased the number of patient visits to hospitals and clinics. In addition, increasing malnutrition is expected to further boost the demand for enteral feeding formulas in this region.

Furthermore, in Asia Pacific, the market is expected to exhibit lucrative growth over the forecast period. The increasing incidence of preterm births is one of the major factors that propel the regional demand. According to the World Health Organization (WHO), India, China, Nigeria, Pakistan, and Indonesia are among the top five countries with the largest number of preterm births. Factors such as increasing healthcare expenditure and recent improvements in healthcare infrastructure in many countries including China, Japan, India, and Singapore are anticipated to drive the market in the forthcoming years.

Key Companies & Market Share Insights

The market is characterized by the presence of leading players with strong product portfolios, global presence, and financial performance. For instance, Abbott, headquartered in the U.S. markets and sells its products in more than 150 countries across the globe. In addition, companies are strategically collaborating with other players in the market, in the form of mergers and partnerships, for leveraging their technological capabilities and expanding their product portfolios of enteral foods. Moreover, major players are continuously investing in R&D activities for the development of new products that cater to niche therapeutic areas with higher growth potential to gain a competitive edge. In addition, market entry is challenging for new players as space is dominated by major MNCs with high brand recognition. Some of the prominent players in the enteral feeding formulas market include:

• Abbott

• Danone SA

• Fresenius Kabi

• Nestlé

• Victus, Inc.

• Primus Pharmaceuticals, Inc.

• Meiji Holdings. Co., Ltd.

• Rickett Benckiser Group Plc.

Enteral Feeding Formulas Market Report Scope

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2014 to 2028. For the purpose of this study, Grand View Research, Inc. has segmented the enteral feeding formulas market report on the basis of product, flow type, stage, indication, end-user, and region.

• Product Outlook (Revenue, USD Million, 2014 - 2028)

  • Standard formula

  • Disease-specific formula

• Flow Type Outlook (Revenue, USD Million, 2014 - 2028)

  • Intermittent feeding flow

  • Continuous feeding flow

• Stage Outlook (Revenue, USD Million, 2014 - 2028)

  • Adult

  • Pediatric

• Indication Outlook (Revenue, USD Million, 2014 - 2028)

  • Alzheimer’s

  • Nutrition Deficiency

  • Cancer Care

  • Diabetes

  • Chronic Kidney Diseases

  • Orphan Diseases

  • Dysphagia

  • Pain Management

  • Malabsorption/GI Disorder/Diarrhea

  • Others

• End-user Outlook (Revenue, USD Million, 2014 - 2028)

  • Hospitals

    • Cardiology

    • Neurology

    • Critical Care (ICU)

    • Oncology

    • Others

  • Home Care

• Regional Outlook (Revenue, USD Million, 2014 - 2028)

  • North America

    • U.S.

    • Canada

  • Europe

    • U.K.

    • Germany

    • Italy

    • France

    • Spain

    • Russia

  • Asia Pacific

    • Australia

    • China

    • Japan

    • South Korea

    • India

    • Singapore

    • New Zealand

  • Latin America

    • Mexico

    • Brazil

    • Argentina

  • Middle East Africa

    • South Africa

    • Saudi Arabia

    • UAE